RDNT RadNet, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 790526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.1%
TTM net income YoY-76.1%
TTM EPS YoY-81.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin3.1%
Net margin-0.9%
FCF margin—
EBITDA margin10.6%
Returns
ROE-2.1%
ROA-0.6%
ROIC (approx.)2.8%
Asset turnover0.60x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity1.18x
Current ratio1.49x
Interest coverage0.99x
Cash quality & payout
Operating cash flow / net income-15.54x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.04B | $1.83B | $1.62B | $1.43B | $1.32B |
| Operating income | $61.99M | $104.62M | $98.70M | $46.36M | $82.55M |
| Interest expense | $69.91M | $79.85M | $64.48M | $50.84M | $48.83M |
| Pretax income | $31.91M | $44.86M | $38.81M | $42.97M | $58.88M |
| Income tax | $14.86M | $6.03M | $8.47M | $9.36M | $14.56M |
| Net income | -$18.65M | $2.79M | $3.04M | $10.65M | $24.73M |
| EBITDA | $214.12M | $242.46M | $227.09M | $162.24M | $179.25M |
| EPS (basic) | -0.25 | 0.04 | 0.05 | 0.19 | 0.47 |
| EPS (diluted) | -0.25 | 0.04 | 0.05 | 0.17 | 0.46 |
| Weighted avg. shares (diluted) | 75.19M | 74.76M | 64.66M | 57.32M | 53.42M |
| Balance sheet | |||||
| Cash & equivalents | $767.22M | $740.02M | $342.57M | $127.83M | $134.61M |
| Receivables | $200.32M | $185.82M | $163.71M | $166.36M | $135.06M |
| Current assets | $1.03B | $1.02B | $579.28M | $367.18M | $324.26M |
| PP&E, net | $807.70M | $694.79M | $604.40M | $565.96M | $484.25M |
| Goodwill | $907.66M | $710.66M | $679.46M | $677.66M | $513.82M |
| Intangibles | $148.51M | $81.35M | $90.61M | $106.23M | $56.60M |
| Total assets | $3.76B | $3.29B | $2.69B | $2.43B | $2.06B |
| Current liabilities | $586.76M | $479.71M | $437.45M | $466.72M | $374.78M |
| Short-term debt | $25.42M | $24.69M | $17.97M | $12.40M | $11.16M |
| Long-term debt | $1.06B | $991.57M | $812.07M | $839.34M | $743.50M |
| Total debt | $1.09B | $1.02B | $830.04M | $851.74M | $754.66M |
| Total liabilities | $2.40B | $2.15B | $1.88B | $1.94B | $1.71B |
| Shareholders' equity | $1.09B | $902.31M | $630.70M | $333.00M | $228.90M |
| Net debt | $322.70M | $276.25M | $487.47M | $723.91M | $620.06M |
| Shares outstanding | 77.40M | 74.04M | 67.96M | 57.72M | 53.55M |
| Cash flow statement | |||||
| Operating cash flow | $298.82M | $233.02M | $220.86M | $146.42M | $149.49M |
| Investing cash flow | -$343.87M | -$233.07M | -$201.47M | -$246.95M | -$221.51M |
| Financing cash flow | $72.21M | $397.95M | $195.63M | $93.65M | $104.67M |
| Depreciation & amortization | $152.13M | $137.84M | $128.39M | $115.88M | $96.69M |
| Stock-based compensation | $54.60M | $29.83M | $26.79M | $23.77M | $25.20M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.